Stem Cell Therapy for Peripheral Artery Disease

What This Article Covers

This article explains what stem cell therapy for peripheral artery disease (PAD) and critical limb ischemia (CLI) involves, what the trial evidence shows, and its real limitations. No stem cell product is FDA-approved for PAD or CLI, and the trial record is genuinely mixed — some studies show real improvement in pain and wound healing, while the largest placebo-controlled trial found no benefit in preventing amputation. We lay out that evidence honestly, without overstating what remains experimental.

Peripheral artery disease is narrowing of the arteries that supply blood to the legs, most often from atherosclerosis. In its most severe form — critical limb ischemia, now often called chronic limb-threatening ischemia — blood flow becomes so restricted that patients develop non-healing wounds, rest pain, or tissue death, and roughly a quarter face amputation within a year without restored flow. Standard treatment is angioplasty, stenting, or bypass surgery. Some patients — often called “no-option” patients — have blockages too diffuse or distal for these procedures, and it is largely for this group that researchers have investigated stem and progenitor cell therapy as a way to grow new small blood vessels around the blockage.

How It's Thought to Work

The approach generally involves collecting a patient's own bone marrow or peripheral blood cells — often mononuclear cells or a purified subset called CD34+ progenitor cells — and injecting them into the affected leg's muscle or artery. The theory, called therapeutic angiogenesis, is that these cells secrete growth factors and help form new capillary networks that reroute blood flow around blocked arteries, potentially easing pain, healing ulcers, and reducing amputation risk. Because the cells are typically autologous (the patient's own), the approach avoids immune rejection, part of why it has been tested extensively in CLI, a condition with few remaining options.

What the Evidence Shows

The trial record here is a real mixed bag, worth reading carefully rather than summarizing in one direction. The PROVASA trial, a 40-patient, placebo-controlled pilot study in Circulation: Cardiovascular Interventions, missed its primary endpoint of improving ankle-brachial index, but did find significantly better ulcer healing and reduced rest pain in cell-treated patients at three months — though amputation-free survival did not differ between groups. A 2019 systematic review and meta-analysis in Stem Cell Research & Therapy, pooling 27 randomized controlled trials and nearly 1,200 patients, found a similar pattern: significant improvements in ulcer healing, ankle-brachial index, pain-free walking distance, and rest pain, alongside lower amputation rates overall — but no significant improvement in major limb salvage, and the authors flagged high risk of bias and low-quality evidence, calling for larger, better-designed trials. Set against that is the JUVENTAS trial, one of the largest and most rigorous studies in the field: 160 patients with no-option limb ischemia randomized to repeated bone-marrow cell infusions or placebo. It found no significant benefit — major amputation occurred in 19% of the cell-therapy group versus 13% of the placebo group, a difference trending the wrong way, though not statistically significant. A review in Stem Cells International summarizing this body of work states plainly that there are no FDA-approved therapies for critical limb ischemia. Taken together, the field shows some real, replicated signal on secondary measures like pain and wound healing, but has not yet shown a reliable effect on the outcome that matters most — avoiding amputation.

Who Might Be a Candidate

• Patients with critical limb ischemia who have exhausted standard revascularization (angioplasty, stenting, or bypass)
• People eligible for a registered clinical trial studying cell therapy for PAD or CLI, with monitored outcomes
• Patients evaluated at an academic center with an active vascular regeneration research program
• Individuals facing amputation who want to understand every remaining option, including experimental ones
• Patients willing to undergo a bone marrow or blood collection procedure as part of a study protocol
• Not a good fit: anyone offered stem cell injections outside a clinical trial, at a direct-to-consumer clinic, especially with guaranteed outcomes

Bottom Line

Stem cell therapy for peripheral artery disease remains an active, legitimate area of research — not an established treatment. No product has FDA approval for PAD or CLI, and the FDA has separately taken enforcement action against clinics marketing unapproved stem cell products, warning that evidence does not yet support such uses outside of blood and immune system disorders. Some trials and meta-analyses show genuine, replicated improvement in pain and wound healing, a meaningful signal worth taking seriously. But the largest, most rigorous placebo-controlled trial to date found no benefit on the outcome that matters most: keeping the limb. Anyone considering this therapy should look for enrollment in a registered clinical trial rather than a commercial clinic, and should treat marketing claims of guaranteed limb salvage with real skepticism until larger, better-designed trials report clearer results.